Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Neuromuscul Dis ; 4(1): 77-87, 2017.
Article in English | MEDLINE | ID: mdl-28269789

ABSTRACT

BACKGROUND: Statins have well-known benefits in the prevention of cardiovascular disease, however, 7-29% of patients develop muscle side effects and up to 0.5% develop severe symptoms. Mitochondrial dysfunction has been associated with severe statin-induced myopathy (SM); however, there is a paucity of systematic studies in affected individuals. OBJECTIVES: The goal of this study was to combine clinical and laboratory features with quantitative biochemical and histopathologic studies of skeletal muscle biopsies from SM cases to determine what proportion could be attributed to mitochondrial dysfunction and how many of these had primary respiratory chain defects. METHODS: A retrospective analysis was performed on patient records derived from 279 SM patients whose muscle biopsies were referred to our clinical diagnostic laboratory for analysis. Clinical, histopathologic and biochemical features were compared with two myopathic control groups unexposed to statins: individuals with idiopathic mitochondrial myopathy (MMP; n = 94) and with unknown metabolic myopathy (UMP; n = 86); normal controls were unavailable for this record review study. RESULTS: More SM patients had significantly elevated plasma CK than in the other two groups (p < 0.01). A subset of SM patients (67 of 279; 24%) had histopathologic and/or electron microscopic (EM) evidence for mitochondrial dysfunction in skeletal muscle; more cases were identified by EM than by histochemical analysis. Of 279 cases, 29 (10%) were confirmed to have respiratory chain defects by biochemical analysis; 4 of these had mitochondrial abnormalities by EM. An additional 20 cases had mitochondrial abnormalities by EM without a biochemical diagnosis. CONCLUSIONS: Both primary and secondary mitochondrial dysfunction was found in subsets of SM patients. The fact that respiratory chain defects were not found in most cases with histopathologic mitochondrial abnormalities does not rule out primary mitochondrial disease in these cases, however, it is more likely that secondary effects on mitochondrial structure and function have occurred; molecular analysis may be helpful only in a small number of cases.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Mitochondrial Diseases/metabolism , Muscle, Skeletal/pathology , Muscular Diseases/chemically induced , Adult , Aged , Case-Control Studies , Creatine Kinase/metabolism , Electromyography , Female , Humans , Male , Microscopy, Electron , Middle Aged , Mitochondrial Diseases/complications , Mitochondrial Diseases/pathology , Mitochondrial Myopathies/metabolism , Mitochondrial Myopathies/pathology , Muscle, Skeletal/ultrastructure , Muscular Diseases/complications , Muscular Diseases/metabolism , Muscular Diseases/pathology , Retrospective Studies , Severity of Illness Index
2.
J Immunol ; 198(1): 352-362, 2017 01 01.
Article in English | MEDLINE | ID: mdl-27895180

ABSTRACT

The coordination of macrophage polarization is essential for the robust regenerative potential of skeletal muscle. Repair begins with a phase mediated by inflammatory monocytes (IM) and proinflammatory macrophages (M1), followed by polarization to a proregenerative macrophage (M2) phenotype. Recently, regulatory T cells (Tregs) were described as necessary for this M1 to M2 transition. We report that chronic infection with the protozoan parasite Toxoplasma gondii causes a nonresolving Th1 myositis with prolonged tissue damage associated with persistent M1 accumulation. Surprisingly, Treg ablation during chronic infection rescues macrophage homeostasis and skeletal muscle fiber regeneration, showing that Tregs can directly contribute to muscle damage. This study provides evidence that the tissue environment established by the parasite could lead to a paradoxical pathogenic role for Tregs. As such, these findings should be considered when tailoring therapies directed at Tregs in inflammatory settings.


Subject(s)
Macrophages/immunology , Myositis/immunology , T-Lymphocytes, Regulatory/immunology , Toxoplasmosis/immunology , Adoptive Transfer , Animals , Cell Differentiation/immunology , Female , Flow Cytometry , Lymphocyte Activation/immunology , Macrophage Activation/immunology , Mice , Mice, Inbred C57BL , Muscle, Skeletal/immunology , Muscle, Skeletal/microbiology , Muscle, Skeletal/pathology , Myositis/microbiology , Myositis/pathology , Real-Time Polymerase Chain Reaction , Toxoplasmosis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL